These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 36324149)

  • 21. Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer.
    Daher M; Rezvani K
    Cancer Discov; 2021 Jan; 11(1):45-58. PubMed ID: 33277313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
    Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
    J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages.
    Ebrahimiyan H; Tamimi A; Shokoohian B; Minaei N; Memarnejadian A; Hossein-Khannazer N; Hassan M; Vosough M
    Int Immunopharmacol; 2022 May; 106():108587. PubMed ID: 35149294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy.
    Wang Y; Jin S; Zhuang Q; Liu N; Chen R; Adam SA; Jin J; Sun J
    MedComm (2020); 2023 Dec; 4(6):e422. PubMed ID: 38045827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
    Wang W; Jiang J; Wu C
    Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
    Sabbah M; Jondreville L; Lacan C; Norol F; Vieillard V; Roos-Weil D; Nguyen S
    Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
    Hu Y; Tian ZG; Zhang C
    Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next Generation Natural Killer Cells for Cancer Immunotherapy.
    Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
    Front Immunol; 2022; 13():886429. PubMed ID: 35720306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
    Zhao Y; Zhou X
    Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAR-NK cells: a promising cellular immunotherapy in lymphoma.
    Khanmohammadi S; Rezaei N
    Expert Opin Biol Ther; 2023 Jan; 23(1):37-47. PubMed ID: 36453808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy.
    Yang K; Zhao Y; Sun G; Zhang X; Cao J; Shao M; Liang X; Wang L
    Front Immunol; 2022; 13():1081546. PubMed ID: 36741400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review).
    Peng X; Chen L; Chen L; Wang B; Wang Y; Zhan X
    Exp Ther Med; 2021 Apr; 21(4):340. PubMed ID: 33732313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
    Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
    Front Immunol; 2022; 13():847008. PubMed ID: 35464442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development.
    Bashiri Dezfouli A; Yazdi M; Pockley AG; Khosravi M; Kobold S; Wagner E; Multhoff G
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells.
    Klaihmon P; Luanpitpong S; Kang X; Issaragrisil S
    Cancer Cell Int; 2023 Nov; 23(1):297. PubMed ID: 38012684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural killer cells: a promising immunotherapy for cancer.
    Chu J; Gao F; Yan M; Zhao S; Yan Z; Shi B; Liu Y
    J Transl Med; 2022 May; 20(1):240. PubMed ID: 35606854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.